2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow SLL: new trials by email Literature Review of SLL trials Research Report on SLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma rituximab, bortezomib, cladribine - Lymphoma, Mantle Cell Lymphoma | Phase 2 | Completed | University of Arizona | 24 | 2009-07-07 | 2019-12-30 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Follicular (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia (1) · Leukemia, Prolymphocytic (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Waldenstrom Macroglobulinemia (1)
Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, B-Cell (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Blood Protein Disorders (1)
Bortezomib (1) · Cladribine (1) · Rituximab (1) · veltuzumab (1)
Gilead Sciences (1) · University of Arizona (1)
United States (2)
Daniel O. Persky, MD (1) · William Wegener, MD, PhD (1)
PMID 21173095, PMID 26389849, PMID 29056470
P30CA023074 (1)